Go-ahead for LCT
Tuesday, 21 October, 2008
Living Cell Technologies [ASX: LCT] has received approval from the New Zealand Government to conduct a Phase I/IIa clinical trial of DiabeCell.
NZ's Health Minister, David Cunliffe, has approved the company's application, with the project to be monitored by his ministry.
A parallel Phase I/IIa trial commenced in Russia in 2007.
According to LCT, approval from the NZ Government will also make it easier to obtain approvals to trial the product in other companies.
DiabeCell uses insulin-producing porcine islet cells stored within LCT's proprietary encapsulation technology.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
